Skip to main content

Advertisement

Table 1 Clinical characteristics of the feasibility cohort

From: Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer

Unique ID Age (years) PSA (ng/mL) Prior therapies* Events on FACS Confirmed CTCs by IF
11001 61 1077 L, B, K, O, D, M 1700 22
11002 80 787 L, D+/-Da 294 17
11003 88 124.3 L, B 94 0
11004 76 201.3 L, T, B, N, D 0 0
11005 80 741 L, F, D, M, E vs pl 4 1
11006 58 168.1 L, B, D 0 0
11007 62 34.24 L, B, D, E 3 0
11008 63 1971 L, B, D, M + I 751 17
11009 62 68.45 L, B, D, M 60 4
11010 79 2229 L, B, D, M, Ctx 62 0
11011 71 218.9 L, B, D+/- Af, E 345 23
11012 70 1425 L 290 25
11013 72 50.15 L, B, F, K, O 431 22
11014 81 25.5 L, B, O, T 237 10
11015 80 70.8 L, B, Di, D, S 86 3
  1. *Prior therapies: A = aflibercept, B = bicalutamide, C = cyclophosphamide, Ci = cixutumumab, D = docetaxel, Da = dasatinib, Di = diethylstilbestrol, E = enzalutamide, F = flutamide, K = ketoconazole, L = LHRH agonist, M = mitoxantrone, N = nilutamide, O = orteronel, P = placebo, S = samarium lexidronam, T = tasquinimod.